Table 1 Open in new tab Criteria adopted...

CLI-OPCI II study

In-stent minimum lumen area <4.5 mm²

Dissection thickness >200 μm at the distal stent edge

Distal or proximal reference narrowing (i.e. reference lumen area <4.5 mm² in the presence of significant residual plaque adjacent to stent endings)

FORZA trial

Major stent strut malapposition (>350 μm or >200 μm for a length >600 μm)

Major stent underexpansion (in-stent minimal cross-section area of <75% of the reference lumen area)

Major stent edge dissection (>600 μm in length)

ILUMIEN-IV OPTIMAL PCI trial

Unacceptable stent expansion (minimal stent area <90% of the reference lumen area)

Major intra-stent plaque protrusion and/or thrombus (intraluminal mass protruding at least 0.2 mm within the luminal edge of a stent strut associated with unacceptable stent expansion, as defined above)

Untreated reference segment disease (disease with untreated minimum lumen area <4.5 mm² within 5 mm from the stent edges)

Major edge dissection (≥60° of the circumference of the vessel at site of dissection and ≥3 mm in length)

Major stent malapposition (strut malapposition ≥200 μm associated with unacceptable stent expansion, as defined above)

Table 1

Open in new tab

Criteria adopted for the definition of suboptimal stent implantation in the three studies

CLI-OPCI II study
In-stent minimum lumen area <4.5 mm²
Dissection thickness >200 μm at the distal stent edge
Distal or proximal reference narrowing (i.e. reference lumen area <4.5 mm² in the presence of significant residual plaque adjacent to stent endings)
FORZA trial
Major stent strut malapposition (>350 μm or >200 μm for a length >600 μm)
Major stent underexpansion (in-stent minimal cross-section area of <75% of the reference lumen area)
Major stent edge dissection (>600 μm in length)
ILUMIEN-IV OPTIMAL PCI trial
Unacceptable stent expansion (minimal stent area <90% of the reference lumen area)
Major intra-stent plaque protrusion and/or thrombus (intraluminal mass protruding at least 0.2 mm within the luminal edge of a stent strut associated with unacceptable stent expansion, as defined above)
Untreated reference segment disease (disease with untreated minimum lumen area <4.5 mm² within 5 mm from the stent edges)
Major edge dissection (≥60° of the circumference of the vessel at site of dissection and ≥3 mm in length)
Major stent malapposition (strut malapposition ≥200 μm associated with unacceptable stent expansion, as defined above)

CLI-OPCI II study
In-stent minimum lumen area <4.5 mm²
Dissection thickness >200 μm at the distal stent edge
Distal or proximal reference narrowing (i.e. reference lumen area <4.5 mm² in the presence of significant residual plaque adjacent to stent endings)
FORZA trial
Major stent strut malapposition (>350 μm or >200 μm for a length >600 μm)
Major stent underexpansion (in-stent minimal cross-section area of <75% of the reference lumen area)
Major stent edge dissection (>600 μm in length)
ILUMIEN-IV OPTIMAL PCI trial
Unacceptable stent expansion (minimal stent area <90% of the reference lumen area)
Major intra-stent plaque protrusion and/or thrombus (intraluminal mass protruding at least 0.2 mm within the luminal edge of a stent strut associated with unacceptable stent expansion, as defined above)
Untreated reference segment disease (disease with untreated minimum lumen area <4.5 mm² within 5 mm from the stent edges)
Major edge dissection (≥60° of the circumference of the vessel at site of dissection and ≥3 mm in length)
Major stent malapposition (strut malapposition ≥200 μm associated with unacceptable stent expansion, as defined above)

This Feature Is Available To Subscribers Only